Hopwood Financial Services Inc. Makes New $418,000 Investment in Amgen Inc. (NASDAQ:AMGN)

Hopwood Financial Services Inc. purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,605 shares of the medical research company’s stock, valued at approximately $418,000.

A number of other institutional investors have also recently bought and sold shares of the business. Capital Performance Advisors LLP acquired a new position in Amgen in the 3rd quarter valued at $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the third quarter valued at about $29,000. Centricity Wealth Management LLC bought a new stake in Amgen during the fourth quarter worth about $25,000. Synergy Investment Management LLC acquired a new stake in Amgen during the fourth quarter worth about $34,000. Finally, Heck Capital Advisors LLC bought a new position in Amgen in the 4th quarter valued at about $36,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by insiders.

Amgen Stock Performance

AMGN opened at $318.89 on Wednesday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a market cap of $171.31 billion, a price-to-earnings ratio of 42.24, a PEG ratio of 2.63 and a beta of 0.53. The company’s fifty day moving average price is $288.66 and its two-hundred day moving average price is $299.43. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s payout ratio is 126.09%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on AMGN shares. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Johnson Rice set a $294.00 target price on Amgen in a report on Wednesday, March 5th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Wolfe Research assumed coverage on Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, UBS Group reissued a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.